Olsen Daniel L, Keeney Gary L, Chen Beiyun, Visscher Daniel W, Carter Jodi M
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905.
Hum Pathol. 2017 Sep;67:94-100. doi: 10.1016/j.humpath.2017.07.011. Epub 2017 Jul 22.
The use of prosthetic implants for breast augmentation has become commonplace. Although implants do not increase the risk of conventional mammary carcinoma, they are rarely associated with anaplastic large cell lymphoma. We report 2 cases of breast implant capsule-associated squamous cell carcinoma with poor clinical outcomes. Both patients (56-year-old woman and 81-year-old woman) had long-standing implants (>25 years) and presented with acute unilateral breast enlargement. In both cases, squamous cell carcinoma arose in (focally dysplastic) squamous epithelium-lined breast implant capsules and widely invaded surrounding breast parenchyma or chest wall. Neither patient had evidence of a primary mammary carcinoma or squamous cell carcinoma at any other anatomic site. Within 1 year, one patient developed extensive, treatment-refractory, locoregional soft tissue metastasis, and the second patient developed hepatic and soft tissue metastases and died of disease. There are 2 prior reported cases of implant-associated squamous cell carcinoma in the plastic surgery literature; one provides no pathologic staging or outcome information, and the second case was a capsule-confined squamous cell carcinoma. Together, all 4 cases share notable commonalities: the patients had long-standing breast implants and presented with acute unilateral breast pain and enlargement secondary to tumors arising on the posterior aspect of squamous epithelialized implant capsules. Because of both its rarity and its unusual clinical presentation, implant capsule-associated squamous cell carcinoma may be underrecognized. The aggressive behavior of the tumors in this series underscores the importance of excluding malignancy in patients with long-standing breast implants who present with acute unilateral breast pain and enlargement.
使用假体植入物进行隆胸已变得很常见。虽然植入物不会增加传统乳腺癌的风险,但它们很少与间变性大细胞淋巴瘤相关。我们报告2例与乳房植入物包膜相关的鳞状细胞癌,临床预后较差。两名患者(一名56岁女性和一名81岁女性)都有长期植入物(>25年),并出现急性单侧乳房肿大。在这两例中,鳞状细胞癌均起源于(局灶发育异常的)内衬鳞状上皮的乳房植入物包膜,并广泛侵犯周围乳腺实质或胸壁。两名患者在任何其他解剖部位均未发现原发性乳腺癌或鳞状细胞癌的证据。1年内,一名患者出现广泛的、治疗难治的局部区域软组织转移,第二名患者出现肝转移和软组织转移并死于疾病。整形外科学文献中此前有2例植入物相关鳞状细胞癌的报道;一例未提供病理分期或预后信息,另一例为包膜内鳞状细胞癌。这4例病例共有的显著共同点是:患者有长期的乳房植入物,并因鳞状上皮化植入物包膜后部出现肿瘤而出现急性单侧乳房疼痛和肿大。由于其罕见性和不寻常的临床表现,与植入物包膜相关的鳞状细胞癌可能未得到充分认识。本系列肿瘤的侵袭性行为凸显了在出现急性单侧乳房疼痛和肿大的长期乳房植入物患者中排除恶性肿瘤的重要性。